Forecasting Remission in Membranous Nephropathy: A Nomogram Utilizing Early Dynamic Biomarkers

1

The study evaluated early dynamic biomarkers to predict 12-month remission in patients with PLA2R-related membranous nephropathy.
2

A retrospective analysis included 144 patients treated with rituximab, categorized into remission and non-remission groups based on outcomes.
3

At 1 month post-treatment, non-remission patients showed significantly lower declines in anti-PLA2R antibodies and urinary protein.
4

Multivariate analysis identified urinary protein, anti-PLA2R decline, and albumin increase as independent predictors of remission.
5

The nomogram developed demonstrated excellent discrimination and calibration for predicting remission based on 1-month biomarker changes.

1